DE60021521D1 - Isonipecotamide zur behandlung von integrin vermittelten störungen - Google Patents
Isonipecotamide zur behandlung von integrin vermittelten störungenInfo
- Publication number
- DE60021521D1 DE60021521D1 DE60021521A DE60021521A DE60021521D1 DE 60021521 D1 DE60021521 D1 DE 60021521D1 DE 60021521 A DE60021521 A DE 60021521A DE 60021521 A DE60021521 A DE 60021521A DE 60021521 D1 DE60021521 D1 DE 60021521D1
- Authority
- DE
- Germany
- Prior art keywords
- isonipecotamide
- integrin
- treatment
- mediated interference
- mediated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- DPBWFNDFMCCGGJ-UHFFFAOYSA-N 4-Piperidine carboxamide Chemical compound NC(=O)C1CCNCC1 DPBWFNDFMCCGGJ-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15661799P | 1999-09-29 | 1999-09-29 | |
| US66713400A | 2000-09-21 | 2000-09-21 | |
| PCT/US2000/026163 WO2001023376A1 (en) | 1999-09-29 | 2000-09-22 | Isonipecotamides for the treatment of integrin-mediated disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60021521D1 true DE60021521D1 (de) | 2005-09-01 |
Family
ID=26853350
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60021521T Expired - Lifetime DE60021521T4 (de) | 1999-09-29 | 2000-09-22 | Isonipecotamide zur behandlung von integrin vermittelten störungen |
| DE60021521A Expired - Fee Related DE60021521D1 (de) | 1999-09-29 | 2000-09-22 | Isonipecotamide zur behandlung von integrin vermittelten störungen |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60021521T Expired - Lifetime DE60021521T4 (de) | 1999-09-29 | 2000-09-22 | Isonipecotamide zur behandlung von integrin vermittelten störungen |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7718673B2 (de) |
| EP (1) | EP1133489B9 (de) |
| CN (1) | CN1352641A (de) |
| AR (1) | AR034098A1 (de) |
| AT (1) | ATE300531T1 (de) |
| AU (1) | AU7711000A (de) |
| BR (1) | BR0007183A (de) |
| CA (1) | CA2352957A1 (de) |
| CZ (1) | CZ20011872A3 (de) |
| DE (2) | DE60021521T4 (de) |
| ES (1) | ES2244474T3 (de) |
| HU (1) | HUP0200439A2 (de) |
| NO (1) | NO20012612L (de) |
| NZ (1) | NZ511997A (de) |
| PL (1) | PL347976A1 (de) |
| RU (1) | RU2001114518A (de) |
| WO (1) | WO2001023376A1 (de) |
| YU (1) | YU22802A (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2151618T3 (es) | 1990-11-19 | 2001-01-01 | Monsanto Co | Inhibidores de proteasas retrovirales. |
| JP4617449B2 (ja) | 2002-07-11 | 2011-01-26 | ヴィキュロン ファーマシューティカルズ インコーポレイテッド | 抗菌活性を有するｎ−ヒドロキシアミド誘導体 |
| US20040224986A1 (en) | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
| AU2005229015C1 (en) | 2004-04-02 | 2013-01-17 | The Regents Of The University Of California | Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin |
| JP5710470B2 (ja) * | 2008-05-16 | 2015-04-30 | アラーガン インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 選択的サブタイプアルファ２アドレナリン作用薬及びこれらの使用方法 |
| AU2010275367B2 (en) | 2009-07-24 | 2015-09-03 | The Regents Of The University Of California | Methods and compositions for treating and preventing disease associated with avB5 integrin |
| EA201991676A1 (ru) * | 2017-01-09 | 2020-01-30 | Арделикс, Инк. | Ингибиторы nhe-опосредованного антипорта |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2830555A1 (de) | 1978-07-12 | 1980-03-06 | Bayer Ag | Chinazolinonyl-verbindungen |
| GB8829296D0 (en) | 1988-12-15 | 1989-01-25 | Ici Plc | Anti-tumour compounds |
| JPH04334357A (ja) * | 1991-05-02 | 1992-11-20 | Fujirebio Inc | 酵素阻害作用を有するアシル誘導体 |
| EP0617705B1 (de) | 1991-11-22 | 1997-09-24 | Yeda Research And Development Company, Ltd. | Nicht-peptidische surrogate der arg-gly-asp sequenz und entsprechende pharmazeutische zusammensetzungen |
| DE4208051A1 (de) * | 1992-03-13 | 1993-09-16 | Bayer Ag | Substituierte phenylessigsaeureamide |
| AU675689B2 (en) * | 1992-12-01 | 1997-02-13 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| US6268380B1 (en) | 1993-02-19 | 2001-07-31 | G. D. Searle & Co. | Urea derivatives useful as platelet aggregation inhibitors |
| DE4309867A1 (de) * | 1993-03-26 | 1994-09-29 | Cassella Ag | Neue Harnstoffderivate, ihre Herstellung und Verwendung |
| GB9313268D0 (en) * | 1993-06-28 | 1993-08-11 | Zeneca Ltd | Chemical compounds |
| ES2164109T3 (es) | 1993-09-22 | 2002-02-16 | Fujisawa Pharmaceutical Co | Derivados de n-(3-piperidinilcarbonil)-beta-alanina como antagonistas de paf. |
| EP0760658B1 (de) | 1994-05-27 | 2002-11-13 | Merck & Co. Inc. | Präparate zur hemmung der durch osteoklasten vermittelten knochenresorption |
| EE9700141A (et) * | 1994-12-23 | 1997-12-15 | Dr. Karl Thomae Gmbh | Piperasiinderivaadid, neid sisaldavad ravimid, nende kasutamine ja valmistamise meetod |
| US5700801A (en) * | 1994-12-23 | 1997-12-23 | Karl Thomae, Gmbh | Piperazine derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
| US5602155A (en) * | 1995-01-17 | 1997-02-11 | G. D. Searle & Co. | Platelet aggregation inhibitors |
| AU726793B2 (en) | 1995-08-14 | 2000-11-23 | Scripps Research Institute, The | Methods and compositions useful for inhibition of alpha v beta 5 mediated angiogenesis |
| MX9801716A (es) | 1995-08-30 | 1998-05-31 | Searle & Co | Derivados de meta-guanidina, urea, tiourea o acido aminobenzoico azaciclico, como antagonistas de integrina. |
| US6100423A (en) * | 1995-08-30 | 2000-08-08 | G. D. Searle & Co. | Amino benzenepropanoic acid compounds and derivatives thereof |
| JPH11513382A (ja) * | 1995-10-20 | 1999-11-16 | ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング | ５員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法 |
| DE19548709A1 (de) | 1995-12-23 | 1997-07-03 | Merck Patent Gmbh | Tyrosinderivate |
| AU2536097A (en) * | 1996-03-29 | 1997-10-22 | G.D. Searle & Co. | Para-substituted phenylpropanoic acid derivatives as integrin antagonists |
| PL190796B1 (pl) * | 1996-05-01 | 2006-01-31 | Ortho Mcneil Pharm Inc | Karboksyamidowe pochodne piperydyny do leczenia zaburzeń zakrzepicowych |
| DE19642591A1 (de) | 1996-10-15 | 1998-04-16 | Basf Ag | Neue Piperidin-Ketocarbonsäure-Derivate, deren Herstellung und Anwendung |
| JP3841898B2 (ja) * | 1996-11-21 | 2006-11-08 | 三菱電機株式会社 | 深部線量測定装置 |
| CA2272090A1 (en) | 1996-12-09 | 1998-06-18 | Matthew J. Fisher | Integrin antagonists |
| AR011913A1 (es) | 1997-03-06 | 2000-09-13 | Yamano Masaki | Derivados de 4,4-difluoro-2,3,4,5-tetrahidro-1h-1-benzoazepina y composiciones farmaceuticas de los mismos. |
| CN1280574A (zh) | 1997-10-27 | 2001-01-17 | 雷迪研究基金会 | 新的杂环化合物及其在医药中的应用、它们的制备方法和含有它们的药物组合物 |
| US6066651A (en) | 1997-10-29 | 2000-05-23 | Ortho-Mcneil Pharmaceutical, Inc. | Orally-active nipecotamide glycolamide esters for the treatment of thrombosis disorders |
| WO1999025685A1 (en) | 1997-11-18 | 1999-05-27 | Merck & Co., Inc. | 4-substituted-4-piperidine carboxamide derivatives |
| EP1054871A2 (de) | 1998-04-01 | 2000-11-29 | Du Pont Pharmaceuticals Company | Pyrimidine und triazine als integrinantagonisten |
| PL194560B1 (pl) | 1998-05-11 | 2007-06-29 | Novo Nordisk As | Związki o właściwościach uwalniania hormonu wzrostu, kompozycja farmaceutyczna zawierająca te związki oraz ich zastosowanie |
| TW591026B (en) * | 1998-06-23 | 2004-06-11 | Upjohn Co | Inhibitors of alpha4beta1 mediated cell adhesion |
| US6388054B1 (en) | 1998-08-20 | 2002-05-14 | John M. Stewart | Anti-cancer compounds |
| AU2164300A (en) | 1998-12-04 | 2000-06-26 | N.V. Organon | Substituted thiazoles for treatment of human diseases involving modulators of p-, l- and e- selectin |
| EP1208101A4 (de) | 1999-08-06 | 2003-03-19 | Smithkline Beecham Corp | Zur behandlung von schlaganfällen nützliche vitronektin-rezeptor-antagonisten |
| JP2003506562A (ja) | 1999-08-10 | 2003-02-18 | ザ、プロクター、エンド、ギャンブル、カンパニー | 洗浄水溶性低密度フィラー粒子を含有する非水性液体洗剤 |
-
2000
- 2000-09-22 BR BR0007183-8A patent/BR0007183A/pt not_active IP Right Cessation
- 2000-09-22 AU AU77110/00A patent/AU7711000A/en not_active Abandoned
- 2000-09-22 CZ CZ20011872A patent/CZ20011872A3/cs unknown
- 2000-09-22 AT AT00966823T patent/ATE300531T1/de not_active IP Right Cessation
- 2000-09-22 CA CA002352957A patent/CA2352957A1/en not_active Abandoned
- 2000-09-22 RU RU2001114518/04A patent/RU2001114518A/ru not_active Application Discontinuation
- 2000-09-22 ES ES00966823T patent/ES2244474T3/es not_active Expired - Lifetime
- 2000-09-22 NZ NZ511997A patent/NZ511997A/xx unknown
- 2000-09-22 HU HU0200439A patent/HUP0200439A2/hu unknown
- 2000-09-22 DE DE60021521T patent/DE60021521T4/de not_active Expired - Lifetime
- 2000-09-22 WO PCT/US2000/026163 patent/WO2001023376A1/en active IP Right Grant
- 2000-09-22 CN CN00803033A patent/CN1352641A/zh active Pending
- 2000-09-22 DE DE60021521A patent/DE60021521D1/de not_active Expired - Fee Related
- 2000-09-22 PL PL00347976A patent/PL347976A1/xx not_active Application Discontinuation
- 2000-09-22 EP EP00966823A patent/EP1133489B9/de not_active Expired - Lifetime
- 2000-09-28 AR ARP000105121A patent/AR034098A1/es unknown
- 2000-09-29 YU YU22802A patent/YU22802A/sh unknown
-
2001
- 2001-05-28 NO NO20012612A patent/NO20012612L/no not_active Application Discontinuation
-
2003
- 2003-01-16 US US10/345,808 patent/US7718673B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2352957A1 (en) | 2001-04-05 |
| DE60021521T2 (de) | 2006-06-08 |
| AR034098A1 (es) | 2004-02-04 |
| DE60021521T4 (de) | 2006-09-21 |
| HUP0200439A2 (en) | 2002-06-29 |
| ATE300531T1 (de) | 2005-08-15 |
| YU22802A (sh) | 2005-06-10 |
| RU2001114518A (ru) | 2003-04-20 |
| NO20012612L (no) | 2001-07-17 |
| NZ511997A (en) | 2004-12-24 |
| EP1133489A1 (de) | 2001-09-19 |
| CN1352641A (zh) | 2002-06-05 |
| US20030181440A1 (en) | 2003-09-25 |
| NO20012612D0 (no) | 2001-05-28 |
| PL347976A1 (en) | 2002-05-06 |
| CZ20011872A3 (cs) | 2002-03-13 |
| ES2244474T3 (es) | 2005-12-16 |
| EP1133489B9 (de) | 2006-05-03 |
| AU7711000A (en) | 2001-04-30 |
| BR0007183A (pt) | 2002-02-05 |
| EP1133489B1 (de) | 2005-07-27 |
| WO2001023376A1 (en) | 2001-04-05 |
| US7718673B2 (en) | 2010-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60019556D1 (de) | 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit | |
| DE60019555D1 (de) | 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit | |
| ATE538096T1 (de) | Pyridinon-derivate zur behandlung von arteriosklerose | |
| ATE275145T1 (de) | Chinazolinderivate zur behandlung von tumoren | |
| DE60011570D1 (de) | Arylpiperazinyl-cyclohexyl indolderivate zur behandlung von depressionen | |
| DE50009504D1 (de) | Verwendung von retigabin zur behandlung von neuropathischen schmerzen | |
| ATE394103T1 (de) | Verwendung von rosuvastatin (zd-4522) zur behandlung von heterozygoter familiärer hypercholesterolämie | |
| DE60045386D1 (de) | Gerät zur thermischen behandlung von bandscheiben | |
| ATE300597T1 (de) | Behandlung von geweben | |
| DE60029033D1 (de) | Verfahren zur Behandlung von Tissuepapier | |
| DE10082139T1 (de) | Zusammensetzung zur Behandlung von Reibungspaaren | |
| DE60136477D1 (de) | Retinoide zur behandlung von emphysem | |
| DE60030554T8 (de) | Verwendungen von et743 zur behandlung von krebs | |
| DE50014041D1 (de) | Verwendung von epinastin zur behandlung von allergischer rhinitis/konjunktivitis | |
| ATE279386T1 (de) | Retinoide zur behandlung von emphysem | |
| DE60035326D1 (de) | Verfahren zur Behandlung von Abwasser | |
| DE50006142D1 (de) | Verfahren zur thermischen Behandlung von mehlförmigen Rohmaterialien | |
| DE60027429D1 (de) | Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien | |
| DE50105735D1 (de) | Chlorzoxazon zur behandlung von psoriasis | |
| DE60104791D1 (de) | Cyclobutendion-Derivate zur Behandlung von Artherosclerose | |
| DE69939723D1 (de) | Verwendung von Intereferon Gamma zur Behandlung von Herzhypertrophie | |
| DE60021252D1 (de) | Antikonvulsiva zur behandlung von autismus | |
| DE60001255D1 (de) | Zusammensetzung zur Behandlung von Polyesterfaser | |
| DE60021521D1 (de) | Isonipecotamide zur behandlung von integrin vermittelten störungen | |
| DE60026821D1 (de) | Behandlung von bohrspülung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8328 | Change in the person/name/address of the agent |
Representative=s name: BOEHMERT & BOEHMERT, 28209 BREMEN |
|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |